Arnaud DeladeriereDirector of Process Development at Triumvira Immunologics Inc.
Arnaud Deladeriere is the Director of Process Development at Triumvira Immunologics Inc., a clinical stage biotech company focusing on the development of the TAC technology, a T-Cell Antigen Coupler that allows T cells to recognize tumors and to kill them by co-opting the endogenous TCR receptor. Arnaud’s main focus at Triumvira is to further develop the company’s products, both autologous and allogeneic TAC-T cells, against several tumor antigens such as HER2 (breast, ovarian, colorectal), or Claudin18.2 (GI). He is particularly involved and interested in the full automation of these processes. Prior to Triumvira, Arnaud was working at a Canadian CDMO for Cell and Gene Therapy called C3i Center, based in Montreal, Canada. There, he developed expertise in GMP Manufacturing and Analytical Development of cell-based therapies. Arnaud received his Ph.D. in Cell and Molecular Biology from the University of Cambridge, UK, during which he studied signaling pathways (centered around PI3K) in several immune cell types, sparking his interest for cell-based therapies early on.